MX347331B - Composiciones y metodos para inhibicion de la via jak. - Google Patents

Composiciones y metodos para inhibicion de la via jak.

Info

Publication number
MX347331B
MX347331B MX2013000757A MX2013000757A MX347331B MX 347331 B MX347331 B MX 347331B MX 2013000757 A MX2013000757 A MX 2013000757A MX 2013000757 A MX2013000757 A MX 2013000757A MX 347331 B MX347331 B MX 347331B
Authority
MX
Mexico
Prior art keywords
methods
compositions
inhibition
jak
jak pathway
Prior art date
Application number
MX2013000757A
Other languages
English (en)
Other versions
MX2013000757A (es
Inventor
Hui Li
Yan Chen
Rajinder Singh
Pingyu Ding
Darren John Mcmurtrie
Vanessa Taylor
Thilo J Heckrodt
Rose Yen
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of MX2013000757A publication Critical patent/MX2013000757A/es
Publication of MX347331B publication Critical patent/MX347331B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids RP(=O)(OH)2; Thiophosphonic acids, i.e. RP(=X)(XH)2 (X = S, Se)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Abstract

Compuestos de la fórmula I, composiciones que los contienen, y métodos de uso de los compuestos y composiciones en el tratamiento de condiciones en donde son terapéuticamente útiles la modulación de la vía JAK o la inhibición de JAK quinasas, particularmente JAK 2 y JAK3. También se divulgan métodos para preparar los compuestos.
MX2013000757A 2010-07-28 2011-07-27 Composiciones y metodos para inhibicion de la via jak. MX347331B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36857010P 2010-07-28 2010-07-28
PCT/US2011/045609 WO2012015972A1 (en) 2010-07-28 2011-07-27 Compositions and methods for inhibition of the jak pathway

Publications (2)

Publication Number Publication Date
MX2013000757A MX2013000757A (es) 2013-04-29
MX347331B true MX347331B (es) 2017-04-21

Family

ID=44504225

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013000757A MX347331B (es) 2010-07-28 2011-07-27 Composiciones y metodos para inhibicion de la via jak.
MX2020009397A MX2020009397A (es) 2010-07-28 2013-01-18 Composiciones y metodos para inhibicion de la via jak.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020009397A MX2020009397A (es) 2010-07-28 2013-01-18 Composiciones y metodos para inhibicion de la via jak.

Country Status (20)

Country Link
US (8) US8343954B2 (es)
EP (1) EP2598500B1 (es)
JP (2) JP6073221B2 (es)
KR (1) KR101937495B1 (es)
CN (1) CN103201280B (es)
AR (2) AR082408A1 (es)
AU (1) AU2011282742B2 (es)
BR (1) BR112013001632B1 (es)
CA (1) CA2804199C (es)
DK (1) DK2598500T3 (es)
EA (1) EA201390015A1 (es)
ES (1) ES2880622T3 (es)
IL (1) IL223855A (es)
MX (2) MX347331B (es)
PL (1) PL2598500T3 (es)
PT (1) PT2598500T (es)
RU (1) RU2672100C2 (es)
TW (1) TWI582090B (es)
WO (1) WO2012015972A1 (es)
ZA (1) ZA201300388B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
PE20150621A1 (es) 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PT2598500T (pt) * 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
WO2013152198A1 (en) 2012-04-04 2013-10-10 Rigel Pharmaceuticals, Inc. Protein kinase c inhibitors and uses thereof
US20130310340A1 (en) * 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
AU2014209263B2 (en) * 2013-01-25 2018-11-01 Rigel Pharmaceuticals, Inc. Compounds and methods for treating inflammatory bowel diseases
US9169249B2 (en) 2013-03-14 2015-10-27 Rigel Pharmaceuticals, Inc. Protein kinase C inhibitors and uses thereof
WO2016090079A1 (en) * 2014-12-05 2016-06-09 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2016100452A2 (en) * 2014-12-17 2016-06-23 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2017007658A1 (en) * 2015-07-07 2017-01-12 Rigel Pharmaceuticals, Inc. A combination for immune mediated cancer treatment
WO2019040706A1 (en) * 2017-08-24 2019-02-28 Aclaris Therapeutics, Inc. COMPOSITIONS AND METHODS FOR TREATING VITILIGO
KR20200085303A (ko) * 2017-11-06 2020-07-14 브리스톨-마이어스 스큅 컴퍼니 Hpk1 억제제로서 유용한 이소푸라논 화합물
KR20210012006A (ko) * 2018-05-24 2021-02-02 아스트라제네카 아베 5-((5-메틸-2-((3,4,5-트리메틸페닐)아미노)피리미딘-4-일)아미노)-벤조[d]옥사졸-2(3h)-온의 푸마레이트 염
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
CN110078633B (zh) * 2019-05-24 2021-05-11 爱斯特（成都）生物制药股份有限公司 一种4-氟-3-甲氧基-5-甲基苯胺盐酸盐制备方法
EP4163278A1 (en) * 2020-05-29 2023-04-12 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. Pyrimidine compound as axl inhibitor

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5087240A (en) 1983-08-18 1992-02-11 Drug Delivery Systems Inc. Transdermal drug patch with conductive fibers
US4921475A (en) 1983-08-18 1990-05-01 Drug Delivery Systems Inc. Transdermal drug patch with microtubes
US4738851A (en) 1985-09-27 1988-04-19 University Of Iowa Research Foundation, Inc. Controlled release ophthalmic gel formulation
US5163899A (en) 1987-03-20 1992-11-17 Drug Delivery Systems Inc. Transdermal drug delivery system
US5312325A (en) 1987-05-28 1994-05-17 Drug Delivery Systems Inc Pulsating transdermal drug delivery system
GB8804164D0 (en) 1988-02-23 1988-03-23 Tucker J M Bandage for administering physiologically active compound
US4882150A (en) 1988-06-03 1989-11-21 Kaufman Herbert E Drug delivery system
US5008110A (en) 1988-11-10 1991-04-16 The Procter & Gamble Company Storage-stable transdermal patch
US5088977A (en) 1988-12-21 1992-02-18 Drug Delivery Systems Inc. Electrical transdermal drug applicator with counteractor and method of drug delivery
US5521222A (en) 1989-09-28 1996-05-28 Alcon Laboratories, Inc. Topical ophthalmic pharmaceutical vehicles
ES2055280T3 (es) 1989-12-04 1994-08-16 Searle & Co Sistema monocapa para la administracion transdermica de farmacos.
US5077033A (en) 1990-08-07 1991-12-31 Mediventures Inc. Ophthalmic drug delivery with thermo-irreversible gels of polxoxyalkylene polymer and ionic polysaccharide
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5352456A (en) 1991-10-10 1994-10-04 Cygnus Therapeutic Systems Device for administering drug transdermally which provides an initial pulse of drug
EP0617665B1 (en) 1991-12-18 1999-03-31 Minnesota Mining And Manufacturing Company Multilayered barrier structures
ATE132381T1 (de) 1992-01-29 1996-01-15 Voelkl Franz Ski Ballspielschläger, insbesondere tennisschläger
IL114193A (en) 1994-06-20 2000-02-29 Teva Pharma Ophthalmic pharmaceutical compositions based on sodium alginate
ES2094688B1 (es) 1994-08-08 1997-08-01 Cusi Lab Manoemulsion del tipo de aceite en agua, util como vehiculo oftalmico y procedimiento para su preparacion.
US5700904A (en) 1995-06-07 1997-12-23 Eli Lilly And Company Preparation of an acylated protein powder
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
IT1283911B1 (it) 1996-02-05 1998-05-07 Farmigea Spa Soluzioni oftalmiche viscosizzate con polisaccaridi della gomma di tamarindo
US5800807A (en) 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6197934B1 (en) 1998-05-22 2001-03-06 Collagenesis, Inc. Compound delivery using rapidly dissolving collagen film
GB0016877D0 (en) * 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
TWI329105B (en) * 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1534286T3 (da) 2002-07-29 2010-04-26 Rigel Pharmaceuticals Inc Fremgangsmåder til behandling eller forebyggelse af autoimmune sygdomme med 2,4-pyrimidindiamin-forbindelser
PT1656372E (pt) 2003-07-30 2013-06-27 Rigel Pharmaceuticals Inc Métodos para o tratamento ou prevenção de doenças autoimunes com compostos de 2,4-pirimidinadiamina
AU2006206458B2 (en) 2005-01-19 2012-10-25 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US20060270694A1 (en) * 2005-05-03 2006-11-30 Rigel Pharmaceuticals, Inc. JAK kinase inhibitors and their uses
US20070203161A1 (en) * 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
ZA200710206B (en) * 2005-06-08 2009-12-30 Rigel Pharmaceuticals Inc Compositions and methods for inhibition of the JAK path-way
US8393954B2 (en) 2006-12-29 2013-03-12 Cfph, Llc Top performers
WO2008118822A1 (en) * 2007-03-23 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2009063240A1 (en) * 2007-11-16 2009-05-22 Arrow Therapeutics Limited 2,4-diaminopyrimidine derivatives useful as inhibitors of aurora kinase
PE20150621A1 (es) * 2009-01-23 2015-05-07 Rigel Pharmaceuticals Inc Derivados de 2,4-diamino-pirimidina n2, n4-disustituidos como inhibidores de jak3
PT2598500T (pt) * 2010-07-28 2021-07-22 Rigel Pharmaceuticals Inc Composições e métodos para a inibição da via jak
CA2832611C (en) * 2011-04-12 2019-05-14 Rigel Pharmaceuticals, Inc. Methods for inhibiting allograft rejection

Also Published As

Publication number Publication date
BR112013001632B1 (pt) 2021-05-25
ES2880622T3 (es) 2021-11-25
AU2011282742A1 (en) 2013-02-07
US9067925B2 (en) 2015-06-30
DK2598500T3 (da) 2021-07-26
US11174251B2 (en) 2021-11-16
KR101937495B1 (ko) 2019-01-10
US20150259332A1 (en) 2015-09-17
MX2020009397A (es) 2020-12-03
US20120028923A1 (en) 2012-02-02
AR119882A2 (es) 2022-01-19
EP2598500B1 (en) 2021-05-19
US10479783B2 (en) 2019-11-19
CN103201280A (zh) 2013-07-10
US9920041B2 (en) 2018-03-20
BR112013001632A2 (pt) 2016-05-24
AU2011282742A2 (en) 2013-04-04
JP2017061518A (ja) 2017-03-30
US20220024907A1 (en) 2022-01-27
EA201390015A1 (ru) 2013-07-30
EP2598500A1 (en) 2013-06-05
CN103201280B (zh) 2016-08-10
CA2804199C (en) 2020-05-12
IL223855A (en) 2016-05-31
KR20130132406A (ko) 2013-12-04
RU2672100C2 (ru) 2018-11-12
PT2598500T (pt) 2021-07-22
JP6073221B2 (ja) 2017-02-01
AR082408A1 (es) 2012-12-05
US8343954B2 (en) 2013-01-01
RU2015122016A (ru) 2016-12-27
US20200115371A1 (en) 2020-04-16
ZA201300388B (en) 2013-09-25
PL2598500T3 (pl) 2021-11-29
MX2013000757A (es) 2013-04-29
USRE47396E1 (en) 2019-05-21
US9611260B2 (en) 2017-04-04
WO2012015972A1 (en) 2012-02-02
TWI582090B (zh) 2017-05-11
US20130090310A1 (en) 2013-04-11
TW201209053A (en) 2012-03-01
US20180162848A1 (en) 2018-06-14
CA2804199A1 (en) 2012-02-02
US20170158683A1 (en) 2017-06-08
JP2013536179A (ja) 2013-09-19
AU2011282742B2 (en) 2015-08-27

Similar Documents

Publication Publication Date Title
MX2011007750A (es) Composiciones y metodos para inhibicion de la ruta jak.
MX2020009397A (es) Composiciones y metodos para inhibicion de la via jak.
MX2013001970A (es) Compuestos de pirrolopirimidina y usos de los mismos.
WO2007098507A3 (en) Compositions and methods for inhibition of the jak pathway
MX353257B (es) Compuestos heterociclicos utiles como inhibidores de proteina cinasa-1 dependiente de 3-fosfoinositido (pdk1).
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
TW201129565A (en) Tricyclic heterocyclic compounds, compositions and methods of use thereof
NZ700928A (en) Dna-pk inhibitors
WO2012016186A8 (en) Macrocyclic kinase inhibitors and uses thereof
MY165728A (en) Selective glycosidase inhibitors and uses thereof
PL2250172T3 (pl) Pirolopirazynowe inhibitory kinazy
WO2013134336A3 (en) Inhibition of adaptor associated kinase 1 for the treatment of pain
TW200942543A (en) Pyrrolopyrazine kinase inhibitors
MX336726B (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
MX338489B (es) Derivados de hidantoina utiles como inhibidores de kv3.
TN2011000259A1 (en) Substituted pyrimidines for the treatment of diseases such as cancer
TN2014000016A1 (en) 4 - piperidinyl compounds for use as tankyrase inhibitors
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
WO2010075558A3 (en) Compositions and methods for inhibition of the jak pathway
MX336711B (es) Inhibidores de catecol o-metil transferasa y su uso en el tratamiento de transtornos psicoticos.
JO2822B1 (en) Inhibitors of the enzyme kinase P70 S6 and AKT
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX2013002118A (es) 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA96265C2 (ru) Композиция и способ ингибирования jak пути передачи сигнала

Legal Events

Date Code Title Description
FG Grant or registration